Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Krystal Biotech (KRYS)

Krystal Biotech Q3 net income rises to $79.4 million on $97.8 million in sales

Positive Impact 3 of 5 earnings Written later

Krystal Biotech reported third-quarter 2025 product revenue of $97.8 million, up from $83.8 million a year earlier, and net income of $79.4 million, or $2.66 per diluted share, versus $27.2 million, or $0.91, in the prior-year quarter. Net income was helped by a $31.4 million income tax benefit, and the company had $864.2 million in cash and investments at quarter end.

Key points

  • Q3 2025 product revenue, net was $97.8 million versus $83.8 million in Q3 2024.
  • Q3 2025 net income was $79.4 million ($2.66 diluted per share), including a $31.4 million income tax benefit.
  • Income from operations was $41.4 million versus $22.5 million a year earlier.
  • FY 2025 non-GAAP combined R&D and SG&A expense guidance is $145.0 million to $155.0 million.

The filing

CompanyKrystal Biotech (KRYS)
Form8-K, current report
Filed with the SECNov 3, 2025, 7:04 AM ET
Accession number0001711279-25-000088

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.